Israel Charo
Corporate Officer/Principal bei The University of California, San Francisco
Aktive Positionen von Israel Charo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | 01.01.1991 | - |
Karriereverlauf von Israel Charo
Ehemalige bekannte Positionen von Israel Charo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CHEMOCENTRYX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2014 | - |
| Corporate Officer/Principal | 01.09.2014 | - | |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Private Equity Investor | 15.12.2010 | 15.12.2010 |
| Corporate Officer/Principal | 15.12.2010 | - |
Ausbildung von Israel Charo
| State University of New York at Downstate Medical Center | Doctorate Degree |
| Stony Brook University | Undergraduate Degree |
| University of California, Berkeley | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Corporate Officer/Principal | 3 |
| Private Equity Investor | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Consumer Services | 5 |
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
- Börse
- Insiders
- Israel Charo
- Erfahrung